Close

Exelixis (EXEL), Ipsen Enter into Exclusive Licensing Agreement for Cabozantinib Outside United States, Canada and Japan

March 1, 2016 8:33 AM EST Send to a Friend
Exelixis, Inc. (NASDAQ: EXEL) and Ipsen today jointly announced an exclusive licensing agreement for the commercialization and further development of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login